UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

FORM 10-Q

(Mark one)

For the quarterly period ended: March 31, June 30, 2021 or

For the transition period from ______ to _____

Commission file number: 000-53166

MusclePharm Corporation

(Exact name of registrant as specified in its charter)

(800) (800) 292-3909

(Registrant’s telephone number, including area code)

4500 Park Granada, Suite 202

Calabasas, CA91302

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [  ]☐ Yes [X] ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [  ]☐ Yes [X] ☒ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ]☐ Yes [X] ☒ No

Number of shares of the registrant’s common stock outstanding at May 20,August 11, 2021: 33,479,886 (excludes 875,621 shares of common stock held in treasury).

MusclePharm Corporation

Form 10-Q

TABLE OF CONTENTS

Forward-Looking Statements

Except as otherwise indicated herein, the terms “MusclePharm,” “Company,” “we,” “our” and “us” refer to MusclePharm Corporation and its subsidiaries. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“the Exchange Act”), and Section 27A of the Securities Act of 1933, as amended. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, including our future profits, financing sources and our ability to satisfy our liabilities, our business strategy and plans, and our objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict and are subject to a number of risks, uncertainties and assumptions, including those described in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 29, 2021. Moreover, we operate in a very competitive and rapidly changing environment. In particular, we have experienced a slowdown in sales from our retail customers due to the ongoing COVID-19 pandemic, and we cannot predict the ultimate impact of the COVID-19 pandemic on our business. New risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Note Regarding Trademarks

We have proprietary rights to a number of registered and unregistered trademarks worldwide that we believe are important to our business, including, but not limited to: “MusclePharm” and “FitMiss”. We have, in certain cases, omitted the ®, © and ™ designations for these and other trademarks used in this Form 10-Q. Nevertheless, all rights to such trademarks are reserved. These and other trademarks referenced in this Form 10-Q are the property of their respective owners and they will assert, to the fullest extent under applicable law, their rights thereto.

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

MusclePharm Corporation

Consolidated Balance Sheets

(In thousands, except share and per share data)

The accompanying notes are an integral part of these Consolidated Financial Statements.

MusclePharm Corporation

Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

The accompanying notes are an integral part of these Consolidated Financial Statements.

MusclePharm Corporation

Consolidated Statements of Changes in Stockholders’ Deficit

(In thousands, except share data)

(Unaudited)

The accompanying notes are an integral part of these Consolidated Financial Statements.

MusclePharm Corporation

Consolidated Statements of Cash FlowsChanges in Stockholders’ Deficit

(Unaudited, in thousands)In thousands, except share data)

(Unaudited)

The accompanying notes are an integral part of these Consolidated Financial Statements.

MusclePharm Corporation

Consolidated Statements of Cash Flows

(Unaudited, in thousands)

The accompanying notes are an integral part of these Consolidated Financial Statements.

MusclePharm Corporation

Notes to Consolidated Financial Statements

(Unaudited)

Note 1. Description of Business

Description of Business

MusclePharm Corporation, was incorporated in Nevada in 2006. Except as otherwise indicated hereintogether with its subsidiaries (the “Company” or the context requires otherwise, the terms “MusclePharm,” the “Company,” “we,” “our” and “us” refer to MusclePharm Corporation and its subsidiaries. The Company“MusclePharm”) is a scientifically-driven, performance lifestyle company that develops, markets and distributes branded sports nutrition products and nutritional supplements that are manufactured by the Company’s co-manufacturers. Our portfolio of recognized brands, including MusclePharm and FitMiss, is marketed and sold globally.

Although theThe Company has historically incurred significant losses and experienced negative cash flows since inception, we generated net incomeinception. As of $0.1 June 30, 2021, the Company had cash of $1.0million, for the period endedan increase of $0.4 million from March 31, 2021 and had cash of $0.6 million, a decline of $1.4 $1.0 million from the December 31, 2020 balance of $2.0 $2.0 million. As of March 31,June 30, 2021, the Company had a working capital deficit of $20.5 $22.8 million, a stockholders’ deficit of $24.3$26.3 million and an accumulated deficit of $192.6 $194.8 million resulting from recurring losses from operations. As a result of our history of losses and financial condition, there is substantial doubt about our ability to continue as a going concern. For financial information concerning more recent periods, see our reports for such periods filed with the SEC.

The Company’s ability to continue as a going concern is dependent upon usit generating profits in the future and/or obtaining the necessary financing to meet ourits obligations and repay our liabilities arising from normal business operations when they come due. ManagementThe Company is evaluating different strategies to obtain financing to fund ourits operations to cover expenses and achievefocus on achieving a level of revenue adequate to support ourits current cost structure. Financing strategies may include, but are not limited to, private placements of capital stock, debt borrowings, partnerships and/or collaborations.

During the fourth quarter of 2019, theThe Company has been focused on cost containment and improving gross margins by focusing on customers with higher margins, reducing product discounts and promotional activity, along with reducing the number of SKU’s and negotiate costpricing for raw materials. TheseIn addition, the Company has worked to negotiate lower production costs with its co-manufacturers. Although these steps improved gross margins inthrough the fourthfirst quarter of 20192021, with the recent increases in commodity prices, primarily protein, the company’s gross margins have been impacted and this trend has continued through March 31, 2021.will continue to be impacted unless commodity prices return the same levels that were seen in 2020.

During 2020, the Company experienced a slowdown in sales from retail customers, including our largest customer, which was partially offset by an increase in sales from our largest online customer. In addition, the Company negotiated lower cost of sold with its co-manufactures.

In 2021, the Company announced its entrance into the functional energy space with its partnership with a former Rockstar Energy executive. The Company plans to launch 3 new energy products in the summer of 2021.

The Company believes with the launch of its new energy products, reductions in operating costs withand continued focus on gross profit and top line sales growth will allow it to ultimately achieve sustained profitability, however,profitability. However, the Company can give no assurances that this will occur. In particular,occur, especially with the cost to launch new energy products along with the recent increase in the cost of protein, which may have a material impact on the Company’s profitability. Additionally, the Company’s profitability andmay be materially impacted by the ability of our third-party manufacturers to meet our customer’scustomers’ demands. In addition,Although, the Company believes entering the functional energy space will help to increase sales and gross margin, however,and reduce exposure to commodity prices, the Company can give no assurances that this will occur. To manage cash flow, the Company has entered into multiple financing arrangements. See additional information in “Note 6. Debt.”

The Company’s results of operations are affected by economic conditions, including macroeconomic conditions and levels of business confidence. There continues to be significant volatility and economic uncertainty in many markets and the ongoing COVID-19 pandemic has increasedcontributes to that level of volatility and uncertainty and has created economic disruption. The Company is actively managing its business to respond to the impact. There were no adjustments recorded in the financial statements that might result from the outcome of these uncertainties.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but may have a material impact on our business, financial condition and results of operations. Management continues to monitor the business environment for any significant changes that could impact the Company’s operations. The Company has taken proactive steps to manage costs and discretionary spending, such as remote working and reducing facility related expense.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these statements do not include all the information and notes required by U.S. GAAP for complete financial statements. The consolidated financial statements include the accounts of MusclePharm Corporationthe Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

The Company’s management believes the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of March 31,June 30, 2021, results of operations for the three and six months ended March 31,June 30, 2021 and 2020, and cash flows for the threesix months ended March 31,June 30, 2021 and 2020. The results of operations for the three and six months ended March 31,June 30, 2021 are not necessarily indicative of the results to be expected for the year ended December 31, 2021.

These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 29, 2021.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, allowance for doubtful accounts, revenue discounts and allowances, the valuation of inventory and deferred tax assets, the assessment of useful lives, recoverability and valuation of long-lived assets, likelihood and range of possible losses on contingencies, present value of lease liabilities, among others. Actual results could differ from those estimates.

Shipping and handling

The Company accounts for shipping and handling costs as fulfillment activities, which are therefore recognized upon shipment of the goods.

For the three and six months ended March 31,June 30, 2021 the Company incurred $0.5  million and $1.0 million, respectively, of inbound shipping and handling costs. For the three and six months ended June 30, 2020 the Company incurred $0.5 $0.4 million and $0.4 $0.8 million, respectively, of inbound shipping and handling costs. Shipping and handling costs related to inbound purchases of raw material and finished goods are included in cost of revenue in our consolidated statements of operations.

For the three and six months ended March 31,June 30, 2021, the Company incurred $0.9 million and $1.6 million, respectively, of shipping and handling costs related to shipments to our customers. For the three and six months ended June 30, 2020, the Company incurred $0.7$0.6 million and $0.6$1.2 million, respectively, of shipping and handling costs related to shipments to our customers. Shipping and handling costs related to shipments to our customers is included in “Selling, general and administrative” expense in our consolidated statements of operations.

Sales discounts and returns

The Company excludes from its revenue any amounts collected from customers for sales (and similar) taxes. During the three months ended March 31,June 30, 2021 and 2020, the Company recorded discounts, and to a lesser degree, sales returns, totaling $2.4 $1.9 million and $4.0 $3.6 million, respectively, which accounted for 15% 11% and 20% 17% of gross revenue in each period, respectively. During the six months ended June 30, 2021 and 2020, the Company recorded discounts, and to a lesser degree, sales returns, totaling $4.4 million and $7.6 million, respectively, which accounted for 14% and 19% of gross revenue in each period, respectively.

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The Company maintains its cash balance at times, may exceed federallycredit-worthy financial institutions that are insured limits.by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. There was an aggregate uninsured cash balance of $0.8 million as of June 30, 2021. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.

Significant customers are those that represent more than 10% of the Company’s revenue, net or accounts receivable for each period presented.

DuringFor the periodthree months ended March 31,June 30, 2021, the Company had two customers who individually accounted for 55% and 13% of net revenue. For the six months ended June 30, 2021, the Company had three customers who individually accounted for 28%43%, 17% 13% and 14% 13% of our net revenue, and two customers thatrevenue. One customer accounted for 32% and 21% 59% of our accounts receivable, net as of March 31,June 30, 2021. During

For the periodthree months ended March 31,June 30, 2020, the Company had three customers who individually accounted for approximately 36%30%, 24% and 21% and 10% of our net revenue andrevenue. For the six months ended June 30, 2020, the Company had three customers thatwho individually accounted for 30%33%, 23% and 14% 16% of ournet revenue. Three customers accounted for 31%, 18% and 16% of accounts receivable, net as of March 31,June 30, 2020.

The Company uses a limited number of non-affiliated suppliers for contract manufacturing of its products. DuringFor the periodthree months ended March 31,June 30, 2021, the Company had three suppliers who individually accounted for approximately 32%23%, 21% 15% and 21% 13% of ourits purchases with contract manufacturesmanufacturers and raw material providers. DuringFor the periodsix months ended March 31, 2020,June 30, 2021, the Company had fourthree suppliers who individually accounted for approximately 34%24%, 30%, 13% 15% and 11% 15% of ourits purchases with contract manufacturesmanufacturers and raw material providers. Four customers accounted for 33%, 17%, 12% and 11% of accounts payable as of June 30, 2021.

For the three months ended June 30, 2020, the Company had three suppliers who individually accounted for approximately 33%, 30% and 20% of its purchases with contract manufacturers and raw material providers. For the six months ended June 30, 2020, the Company had three suppliers who individually accounted for approximately 34%, 30% and 17% of its purchases with contract manufacturers and raw material providers. Three customers accounted for 19%, 12% and 12% of accounts payable as of June 30, 2020.

Recent Accounting Pronouncements

In July 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which among other things, these amendments requirerequires the measurement of all expected credit losses of financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. In addition, the ASU amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. ASU 2016-13 is effective for periods beginning after December 15, 2022, and interim periods within those fiscal years. The Company will evaluateis currently evaluating the impact of the pronouncement closer to the effective date.this ASU may have on its consolidated financial statements.

In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. This guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but not earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The FASB also specified that an entity should adopt the guidance as of the beginning of its annual fiscal year and is not permitted to adopt the guidance in an interim period. The Company will evaluateis currently evaluating the impact of the pronouncement closer to the effective date.this ASU may have on its consolidated financial statements.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company will evaluateis currently evaluating the impact of the pronouncement closer to the effective date.this ASU may have on its consolidated financial statements.

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which was expected to reduce cost and complexity related to the accounting for income taxes. The ASU removes specific exceptions to the general principles in Topic 740 in U.S. GAAP. It eliminates the need for an organization to analyze whether the following apply in a given period: exception to the incremental approach for intra-period tax allocation; exceptions to accounting for basis differences when there are ownership changes in foreign investments; and exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also improves financial statement preparers’ application of income tax-related guidance and simplifies U.S. GAAP for: franchise taxes that are partially based on income; transactions with a government that result in a step up in the tax basis of goodwill; separate financial statements of legal entities that are not subject to tax; and enacted changes in tax laws in interim periods. The Company adopted this ASU effective January 1, 2021, with certain provisions applied retrospectively and other provisions applied prospectively. Adoption of this ASU did not have a material impact to the Company’s condensed consolidated balance sheet, statements of operations, or cash flows.

Reclassifications.

Certain prior period amounts have been reclassified to conform to the current period financial statement presentations, including classification of certain labilities. These changes in presentation did not have a material impact on the Company's financial condition or results of operations.

Note 3. Inventory

Inventory consisted solely of finished goods and raw materials used to manufacture our products by one of our co-manufacturers (in thousands):

Schedule of Inventory

Note 3. 4. Accrued and Other Liabilities

As of March 31,June 30, 2021 and December 31, 2020, the Company’s accrued and other liabilities consisted of the following (in thousands):

(in thousands):Schedule of Accrued and Other Liabilities

Note 4. 5. Interest and other expense, net

For the three months ended March 31,June 30, 2021 and 2020, “Interest and other expense, net” consisted of the following (in thousands):

Schedule of Interest and Other Expense, Net

“Other” includes sublease income.

Note 6. Leases

Note 5. Leases

A summary of the Company’s lease portfolio as of March 31,June 30, 2021 and December 31, 2020 is presented in the table below (in thousands):

Fixed lease costs represent the explicitly quantified lease payments prescribed by the lease agreement and are included in the measurementSchedule of the ROU asset and corresponding lease liability. Some leasing arrangements require variable payments that are dependent on usage, output, or may vary for other reasons, such as insurance and tax payments. The variable lease payments are not presented as part of the initial ROU asset or lease liability. The Company’s lease agreements do not contain any material restrictive covenants.Supplemental Balance Sheet Information

The components of lease cost for operating and finance leases for the three months ended March 31, 2021 and 2020 were as follows (in thousands):

The Company had no short-term leases as of both March 31, 2021 and 2020. The Company’s leases do not provide an implicit rate; therefore, the Company uses its incremental borrowing rate based on the information available at the effective date in determining the present value of future payments for those leases.

Supplemental cash flow information related to leases was as follows:

Schedule of Supplemental Cash Flow Information

Note 7. Other Long-Term Liabilities

Note 6. Debt

As of March 31,June 30, 2021, and December 31, 2020, the Company’s debtother long-term liabilities consisted of the following (in thousands):

Schedule of Other Long-Term Liabilities

Note 8. Debt

Related-Party Refinanced Convertible Note

On November 29, 2020, the Company entered into a refinancing agreement with Mr. Ryan Drexler, the Company’s Chairman of the Board of Directors and Chief Executive Officer (the “November 2020 Refinancing”), in which the Company issued to Mr. Drexler a convertible secured promissory note (the November“November 2020 “ConvertibleConvertible Note”) in the original principal amount of $2,871,967,$2,871,967, which amended and restated a convertible secured promissory note dated as of August 21, 2020. The $2.9$2.9 million November 2020 Convertible Note bears interest at the rate of 12% per annum. Unless earlier converted or repaid, all outstanding principal and any accrued but unpaid interest under the November 2020 Convertible Note shall bewas due and payable on July 1, 2021.2021; however, the Company and Mr. Drexler agreed to an extension until July 14, 2022 (see Note 14. Subsequent Events). Any interest not paid when due shall be capitalized and added to the principal amount of the November 2020 Convertible Note and bear interest on the applicable interest payment date along with all other unpaid principal, capitalized interest, and other capitalized obligations.

Mr. Drexler may, at any time, and from time to time, upon written notice to the Company, convert the outstanding principal and accrued interest into shares of Common Stock, at a conversion price of $0.23$0.23 per share. At the election of the Company, one-sixth of the interest may be paid in kind (“PIK Interest”) by adding such amount to the principal amount of the note, or through the issuance of shares of the Company’s common stock to Mr. Drexler. The PIK Interest is convertible to common stock at the closing price per share on the last business day of each calendar quarter. In no event will the conversion price of such PIK Interest be less than $0.10.$0.10. The Company may prepay the Note by giving Mr. Drexler between 15- and 60-days’ notice depending upon the specific circumstances, subject to Mr. Drexler’s conversion right. The Company intends to pay all interest due on the Convertible Note to Mr. Drexler at the end of each calendar quarter.

The November 2020 Convertible Note contains customary restrictions on the ability of the Company to, among other things, grant liens or incur indebtedness other than certain obligations incurred in the ordinary course of business. The restrictions are also subject to certain additional qualifications and carveouts, as set forth in the November 2020 Convertible Note. The November 2020 Convertible Note is subordinated to certain other indebtedness ofthe secured borrowing arrangement the Company held byentered into with Prestige Capital Corporation (“Prestige”) and Crossroads Financial Group, LLC (“Crossroads”).

For the three months ended March 31,June 30, 2021 and 2020, interest expense related to the related party convertible secured promissory notesnote was $85,000$0.1 million and $76,000,$0.1 million, respectively. During

For the threesix months ended March 31,June 30, 2021 $85,000 inand 2020, interest expense related to the related party convertible secured promissory note was paid in cash to Mr. Drexler; for the three months ended March 31, 2020, no interest was paid in cash to Mr. Drexler.$0.2 million and $0.2 million, respectively.

Related Party Related-Party Secured Revolving Promissory Note

On October 15, 2020, the Company entered into a secured revolving promissory note (the “Revolving Note”) with Ryan Drexler. Under the terms of the Revolving Note, the Company can borrow up to $3.0$3.0 million. The Revolving Note bears interest at the rate of 12% per annum. The use of funds will bewere used for the purchase of whey protein and other general corporate purposes. Both the outstanding principal, if any, and all accrued interest under the Revolving Note were due on March 31, 2021,2021; however, the Company and Mr. Drexler agreed to an extension until June 30, 2021.2022 (see Note 14. Subsequent Events). The Company may prepay the Revolving Note by giving Mr. Drexler one days’ advance written notice. The Revolving Note contains customary events of default, including, among others, the failure by the Company to make a payment of principal or interest when due. Following an event of default, Mr. Drexler is entitled to accelerate the entire indebtedness under the Revolving Note. The Revolving Note also contains customary restrictions on the ability of the Company to, among other things, grant liens or incur indebtedness other than certain obligations incurred in the ordinary course of business. The restrictions are also subject to certain additional qualifications and carveouts, as set forth in the Revolving Note. The Revolving Note is subordinated to certain other indebtedness ofthe secured borrowing arrangement the Company held by Prestige and Crossroads.entered into with Prestige. In connection with the Revolving Note, the Company and Mr. Drexler entered into a fifth amended and restated security agreement dated October 15, 2020 (the “Security Agreement”) pursuant to which the Revolving Note is secured by all of the assets and properties of the Company and its subsidiaries whether tangible or intangible.

As of March 31,June 30, 2021, the outstanding balance on the revolving note was $1.7$2.5 million. During the periodthree and six months ended March 31,June 30, 2021, interest paid in cash to Mr. Drexler was $16,000.$0.1 million and $0.1 million, respectively.

Secured Borrowing Arrangement

In January 2016, the Company entered into a Purchase and Sale Agreement (the “Purchase and Sale Agreement”) with Prestige, pursuant to which the Company agreed to sell and assign and Prestige agreed to buy and accept, certain accounts receivable owed to the Company (“Accounts”). Under the terms of the Purchase and Sale Agreement, upon the receipt and acceptance of each assignment of Accounts, Prestige will pay the Company 80% of the net face amount of the assigned Accounts, up to a maximum total borrowing of $12.5$12.5 million subject to sufficient amounts of accounts receivable to secure the loan. The remaining 20% will be paid to the Company upon collection of the assigned Accounts, less any chargebacks (including chargebacks for any customer amounts that remain outstanding for over 90 days), disputes, or other amounts due to Prestige. Prestige’s purchase of the assigned Accounts from the Company will be at a discount fee which varies from 0.7% to 4%, based on the number of days outstanding from the assignment of Accounts to collection of the assigned Accounts. In addition, the Company granted Prestige a continuing security interest in and first priority lien upon all accounts receivable, inventory, fixed assets, general intangibles, and other assets. Prestige will have no recourse against the Company if payments are not made due to the insolvency of an account debtor within 90 days of invoice date, with the exception of international and certain domestic customers. On April 10, 2019, the Company and Prestige amended the terms of the agreement. The agreement was extended until April 1, 2020 and automatically renews for one (1) year periods unless either party receives written notice of cancellation from the other, at minimum, thirty (30) days prior to the expiration date thereafter.

On June 14, 2021, Prestige advanced the Company $1 million with a six-month term, 15% interest rate and 2% accommodation fee.

As of March 31,June 30, 2021, and December 31, 2020, the Company had outstanding borrowings under the secured borrowing arrangement of approximately $4.7$5.3 million and $7.1$7.1 million, respectively.

During the three months ended March 31,June 30, 2021 and 2020, the Company assigned to Prestige, accounts with an aggregate face amount of approximately $11.1 $18.5 million and $11.7 $14.8 million, respectively, for which Prestige paid to the Company approximately $8.8 $14.7 million and $9.4 $11.7 million, respectively, in cash. During the three months ended March 31,June 30, 2021 and 2020, $11.2 $14.2 million and $10.0 $12.6 million, respectively, was repaid to Prestige, including fees and interest.

During the six months ended June 30, 2021 and 2020, the Company assigned to Prestige, accounts with an aggregate face amount of approximately $32.8 million and $26.4 million, respectively, for which Prestige paid to the Company approximately $26.2 million and $21.1 million, respectively, in cash. During the six months ended June 30, 2021 and 2020, $28.0 million and $22.6 million, respectively, was repaid to Prestige, including fees and interest.

Paycheck Protection Program Loan

Due to economic uncertainty as a result of the ongoing pandemic (COVID-19), on May 14, 2020, the Company received an aggregate principal amount of $964,910$964,910 pursuant to the borrowing arrangement (“Note”) with Harvest Small Business Finance, LLC (“HSBF”) and agreed to pay the principal amount plus interest at a 1% fixed interest rate per year, on the unpaid principal balance. The Note includes forgiveness provisions in accordance with the requirements of the Paycheck Protection Program, Section 1106 of the CARES Act.

The Note is expected to mature on May 16, 2023.2025. Payments were due by November 16, 2020 (the “Deferment Period”) and interest was accrued during the Deferment Period. However, the Flexibility Act, which was signed into law on June 5, 2020, extended the Deferment Period to the date that the forgiven amount is remitted by the United States Small Business Administration (“SBA”) to HSBF. The Company is in the process of filling out the forgiveness application form.As of March 31,June 30, 2021, the Company owed approximately $1.0 $1.0 million (principal plus accrued interest). Of this amount, the short-term portion of $0.2 million, which $0.1M is recorded in “Accrued and other liabilities”classified as “short-term” and the remaining liability of $0.8 millionamount is recorded inwithin “Other long-term liabilities” in the consolidated balance sheets.liabilities.”

Note 7. 9. Commitments and Contingencies

Settlements

Manchester City Football Group

The Company was engaged in a dispute with City Football Group Limited (“CFG”), the owner of Manchester City Football Group, concerning amounts allegedly owed by the Company under a sponsorship agreement with CFG (the “Sponsorship Agreement”). In August 2016, CFG commenced arbitration in the United Kingdom against the Company, seeking approximately $8.3$8.3 million for the Company’s purported breach of the Sponsorship Agreement.

On July 28, 2017, the Company approved a Settlement Agreement (the “CFG Settlement Agreement”) with CFG effective July 7, 2017. The CFG Settlement Agreement represents a full and final settlement of all litigation between the parties. Under the terms of the agreement, the Company agreed to pay CFG a sum of $3$3 million, which was recorded as accrued expenses in 2017. The settlement consists of a $1$1 million payment that was advanced by a related party on July 7, 2017, a $1$1 million installment paid on July 7, 2018 and a subsequent $1$1 million installment payment to be paid by July 7, 2019. Of this amount, the Company has remitted $0.3$0.3 million.

During the three months ended March 31,June 30, 2021 and 2020, the Company recorded a charge of $18,000$19,000 and $19,000,$19,000, respectively and during the six months ended June 30, 2021 and 2020, the Company recorded a charge of $38,000 and $38,000, respectively. This charge, representing imputed interest, is included in “Interest and other expense, net” in the Company’s consolidated statements of operations.

Nutrablend Matter

On February 27, 2020, Nutrablend, a manufacturer of MusclePharm products, filed an action against MusclePharmthe Company in the United States District Court for the Eastern District of California, claiming approximately $3.1$3.1 million in allegedly unpaid invoices. These invoices relate to the third and fourth quarter of 2019, and a liability has been recorded in the books for the related periods.

On September 25, 2020, the parties successfully mediated the case to a settlement (the “Nutrablend Agreement”) and the Company agreed to (i) pay approximately $3.1$3.1 million (“Owed Amount”) in monthly payments (“Monthly Payments”) from September 1, 2020 through June 30, 2023 and (ii) issue monthly purchase orders (“Purchase Orders”) at minimum amounts accepted by Nutrablend.

MusclePharm

The Company agreed to issue Purchase Orders in a combined total amount of at least (i) $1,500,000$1,500,000 from September 1, 2020 through November 30, 2020; (ii) $1,800,000$1,800,000 from December 1, 2020 through February 28, 2021; (iii) $2,100,000$2,100,000 from March 31, 2021 through May 31, 2021; (iv) $2,100,000$2,100,000 from June 1, 2021 through August 31, 2021; and (v) $1,400,000$1,400,000 from September 1, 2021 through October 30, 2021. Beginning on November 1, 2021, MusclePharmthe Company will be required to issue monthly Purchase Orders to Nutrablend in a minimum amount of $700,000$700,000 until the Owed Amount is paid in full to Nutrablend. In the event that MusclePharmthe Company pays the Owed Amount in full before September 1, 2021, MusclePharm isits entitled to a rebate on all completed Purchase Orders. Further, once the monthly payments, and any additional payments that MusclePharmthe Company has made on the Owed Amount, reduce the outstanding balance of the Owed Amount to below $2.0$2.0 million, MusclePharmthe Company is eligible for an extension of a line of credit from Nutrablend in an amount of up to $3.0$3.0 million.

On July 7, 2021, the Company commenced an action against Nutrablend in the Central District of California, seeking (i) a declaration that the Nutrablend Agreement purchase order provisions have been terminated due to Nutrablend’s failure to provide the Company with reasonable assurances of its ability to fulfill its purchase orders; (ii) a declaration that approximately $2.0 million in purchase orders that the Company placed in July and August 2020 were intended to and do count towards the minimums set forth in the Nutrablend Agreement; and (iii) damages based on Nutrablend’s failure to fulfill purchase orders. The case is ongoing.

The Company determined that approximately $1.0$1.1 million dollars of the Owed Amount was due within a year, and this amount was recorded in “Accrued and other liabilities” in the consolidated balance sheets. The present value of the remaining Owed Amount that was due after a year was $1.2$1.0 million, and the amount was recorded in “Other long-term liabilities” in the consolidated balance sheets. The Company made payments of $0.5$0.7  million as of March 31,June 30, 2021.

During the periodthree and six months ended March 31,June 30, 2021 the Company recorded interest of $0.1 million and $0.1 million, respectively. This charge, representing imputed interest, is included in “Interest and other expense, of $64,000,net” in the Company’s consolidated statements of operations.

4Excelsior Matter

On March 18, 2019, Excelsior Nutrition, Inc. (“4Excelsior”), a manufacturer of MusclePharm products, filed an action against MusclePharmthe Company in the Superior Court of the State of California for the County of Los Angeles, claiming approximately $6.2$6.2 million in damages relating to allegedly unpaid invoices, as well as approximately $7.8$7.8 million in consequential damages.

On January 27, 2020, MusclePharm filed a counterclaim against 4Excelsior seeking unidentified damages relating to, among other things, 4Excelsior’s failure to fulfill a purchase order. MusclePharm also moved to strike 4Excelsior’s consequential damages on the grounds that they are unrecoverable under the Uniform Commercial Code. The court denied that motion, and the action proceeded to discovery.

On NovemberDecember 16, 2020, the Company and 4Excelsior entered into a stipulation of settlement that provided that the Company would pay to 4Excelsior a total of $4.75 million in four monthly payments of $70,000, beginning January 5, 2021, and thereafter in monthly payments of $0.1 million.

On December 16, 2020, MusclePharm and 4Excelsior entered into a Settlement Agreement and Mutual Release (“the Agreement”), pursuant to which the parties resolved and settled the civil action pending in the Superior Court of the State of California for the County of Los Angeles (the “Litigation”). The parties agreed to a mutual general release of claims and to jointly file within 10 business days of the effective date of the Agreement a stipulation and proposed order of dismissal, dismissing with prejudice all claims and counterclaims asserted in the Litigation. MusclePharmThe Company agreed to pay $4.75$4.75 million (the “Settlement Amount”) in four monthly payments of $70,000,$70,000, beginning January 5, 2021, and thereafter in monthly payments of $0.1$0.1 million until the Settlement Amount is fully paid. MusclePharmThe Company may prepay all or any portion of the Settlement Amount at any time without penalty or premium. The Agreement provides that, in the event of a Default (as defined in the Agreement) by MusclePharm,the Company, the entire outstanding balance of the Settlement Amount will become immediately due and payable, plus accrued interest at a rate of 18% per annum, commencing from the date of default.

The Company determined that approximately $1.1$1.1 million dollars of the Settlement Amount was due within a year, and this amount was recorded in “Accrued and other liabilities” in the consolidated balance sheets. The present value of the remaining Settlement Amount that was due after a year was $2.4$2.2 million, and the amount was recorded in “Other long-term liabilities” in the consolidated balance sheets. The Company made payments of $0.2$0.8  million as of March 31,June 30, 2021.

During the periodthree and six months ended March 31,June 30, 2021, the Company recorded interest expense of $0.1$0.1 million and $0.2 million, respectively, in the consolidated statements of operations.

Contingencies

In the normal course of business or otherwise, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. The Company provides disclosures for material contingencies when there is a reasonable possibility that a loss or an additional loss may be incurred. In assessing whether a loss is a reasonable possibility, the Company may consider the following factors, among others: the nature of the litigation, claim or assessment, available information, opinions or views of legal counsel and other advisors, and the experience gained from similar cases. As of March 31,June 30, 2021, the Company was involved in the following material legal proceedings described below.

ThermoLife International

In January 2016, ThermoLife International LLC (“ThermoLife”), a supplier of nitrates to MusclePharm,the Company, filed a complaint against usthe Company in Arizona state court. ThermoLife alleged that wethe Company failed to meet minimum purchase requirements contained in the parties’ supply agreement. In March 2016, we filed counterclaims alleging that ThermoLife’s products were defective. Through orders issued in September and November 2019, the court dismissed MusclePharm’s counterclaims and found that the Company was liable to ThermoLife for failing to meet its minimum purchase requirements.

The court held a bench trial on the issue of damages in October 2019, and on December 4, 2019, the court entered judgment in favor of ThermoLife and against the Company in the amount of $1.6$1.6 million, comprised of $0.9$0.9 million in damages, interest in the amount of $0.3$0.3 million and attorneys’ fees and costs in the amount of $0.4$0.4 million. The Company recorded $1.6$1.6 million in accrued expenses in 2018. As of December 31, 2020,June 30, 2021, the total amount accrued, including interest, was $1.8$1.8 million. In the interim, theThe Company has filed an appeal and posted bonds in the total amount of $0.6$0.6 million in order to stay execution on the judgment pending appeal. Of the $0.6 million, $0.25$0.25 million (including fees) was paid by Mr. Drexler on behalf of the Company. See “Note 8. Debt” for additional information. The balance of $0.35$0.35 million was secured by a personal guaranty from Mr. Drexler, while the associated feesannual fee of $12,500 were$12,500 has been paid by the Company. On April 27, 2021, the appellate court issued a decision largely affirming the trial court judgement, except vacating the judgement’s $0.3$0.3 million prejudgment interest award and remanding for a recalculation of prejudgment interest. On May 18, 2021, ThermoLife filed a motion asking the trial court to increase MusclePharm’sthe Company’s appeal bond to the full amount of the judgment, or $1.8$1.8 million, which MusclePharm intends to vigorously oppose.the Court denied on June 2, 2021.

For both the three months ended March 31,June 30, 2021 and 2020, interest expense recognized by the Company on the awarded damages was $22,000.$22,000 and for both the six months ended June 30, 2021 and 2020, interest expense recognized by the Company on the awarded damages was $44,000.

The Company intends to vigorously continue pursuing its defenses, including an appeal todefenses. On June 25, 2021, the Company filed a petition for review in the Arizona Supreme Court which it has until June 25, 2021 to file arequesting that the Court accept review of the appeal affirming the judgment against the Company. ThermoLife opposed the petition for review on July 26, 2021. The Arizona Supreme Court has not yet ruled on the Company’s petition for review.

White Winston Select Asset Fund Series MP-18, LLC et al., v. MusclePharm Corp., et al., (Nev. Dist. Ct.; Cal. Superior Court; Colorado Dist. Ct.; Mass. Super. Ct.)

On August 21, 2018, White Winston Select Asset Fund Series MP-18, LLC and White Winston Select Asset Fund, LLC (together “White Winston”) initiated a derivative action against MusclePharmthe Company and its directors (the “director defendants”). White Winston alleges that the director defendants breached their fiduciary duties by improperly approving the refinancing of three promissory notes issued by MusclePharmthe Company to Mr. Drexler (the “Amended Note”) in exchange for $18.0$18.0 million in loans. White Winston alleges that this refinancing improperly diluted their economic and voting power and constituted an improper distribution in violation of Nevada law. In its complaint, White Winston sought the appointment of a receiver over MusclePharm,the Company, a permanent injunction against the exercise of Mr. Drexler’s conversion right under the Amended Note, and other unspecified monetary damages. On September 13, 2018, White Winston filed an amended complaint, which added a former MusclePharm executive of the Company, as a plaintiff (together with White Winston, the “White Winston Plaintiffs”). On December 9, 2019, the White Winston Plaintiffs filed a Second Amended Complaint, in which they added allegations relating to the resignation of MusclePharm’sthe Company’s auditor, Plante & Moran PLLC (“Plante Moran”). MusclePharmthe Company has moved to dismiss the Second Amended Complaint. That motion has not yet been fully briefed.

Along with its complaint, White Winston also filed a motion for a temporary restraining order (“TRO”) and preliminary injunction enjoining the exercise of Mr. Drexler’s conversion right under the Amended Note. On August 23, 2018, the Nevada district court issued an ex parte TRO. On September 14, 2018, the court let the TRO expire and denied White Winston’s request for a preliminary injunction, finding, among other things, that White Winston did not show a likelihood of success on the merits of the underlying action and failed to establish irreparable harm. Following the court’s decision, MusclePharmthe Company filed a motion seeking to recoup the legal fees and costs it incurred in responding to the preliminary injunction motion. On October 31, 2019, the court awarded MusclePharm $56,000the Company $56,000 in fees and costs.

Due to the uncertainty associated with determining our liability, if any, and due to our inability to ascertain with any reasonable degree of likelihood, as of the date of this report, the outcome of the trial, the Company has not recorded an estimate for its potential liability.

On June 17, 2019, White Winston moved for the appointment of a temporary receiver over MusclePharm,the Company, citing Plante Moran’s resignation. The court granted White Winston’s request to hold an evidentiary hearing on the motion, but subsequently stayed the action pending the parties’ attempts to resolve their dispute. Although the parties have been unable to reach a resolution, the litigation has not yet resumed. On July 30, 2019, White Winston filed an action in the Superior Court of the State of California in and for the County of Los Angeles, seeking access to MusclePharm’sthe Company’s books and records and requesting the appointment of an independent auditor for the company. On February 25, 2021, the court ordered MusclePharmthe Company to produce certain documents, denied White Winston’s request for an auditor, and ordered MusclePharmthe Company to pay a $1,500$1,500 penalty. On July 20, 2021 the California court awarded White Winston also seeks its$92,942 in attorneys’ fees and cost relating to the books-and-records action. The Company paid the amounts due on July 30, 2021, and on August 4, 2021 White Winston submitted a filing acknowledging that the California court’s judgment has been fully satisfied.

MusclePharm intends to challenge White Winston’s request for fees and costs.

IRS Audit

On April 6, 2016, the Internal Revenue Service (“IRS”) selected our 2014 Federal Income Tax Return for audit. As a result of the audit, the IRS proposed certain adjustments with respect to the tax reporting of our former executives’ 2014 restricted stock grants. Due to the Company’s current and historical loss position, the proposed adjustments would have no material impact on the Company’s Federal income tax. On October 5, 2016, the IRS commenced an audit of our employment and withholding tax liability for 2014. The IRS contendscontended that the Company inaccurately reported the value of the restricted stock grants and improperly failed to provide for employment taxes and Federal tax withholding on these grants. In addition, the IRS is proposingproposed certain penalties associated with the Company’s filings. On April 4, 2017, the Company received a “30-day letter” from the IRS asserting back taxes and penalties of approximately $5.3$5.3 million, of which $4.4$4.4 million related to withholding taxes, specifically, income withholding and Social Security taxes, and $0.9$0.9 million related to penalties. Additionally, the IRS assertsasserted that the Company owes information reporting penalties of approximately $2.0$2.0 million.

The Company’s counsel has submitted a formal protest to the IRS disputing on several grounds all of the proposed adjustments and penalties on the Company’s behalf, and the Company has been pursuingpursued this matter vigorously through the IRS appeal process. An Appeals Conference was held with the IRS in Denver, Colorado on July 31, 2019. At the conference, the Company made substantial arguments challenging the IRS’s claims for employment taxes and penalties. On December 16, 2019, a further Appeals Conference was held with the IRS by telephone. At the telephone conference, the Appeals Officer confirmed that he agreed with the Company’s argument that the failure to deposit penalties should be conceded by the IRS. The failure to deposit penalties total about $2$2 million. Thus, with this concession, the IRS’s claims have been reduced from approximately $7.3$7.3 million to about $5.3$5.3 million.

The remaining issue in dispute in this matter involvesinvolved the fair market value of restricted stock units in the Company granted to certain former officers (the “Former Officers”) of the Company under Internal Revenue Code § 83. The Company and the IRS disagreedisagreed as to the value of the restricted stock on the date of the grants, i.e., October 1, 2014. The Company and the IRS have exchanged expert valuation reports on the fair market value of the stock and have had extensive negotiations on this issue. The parties, however, have not been able to reach an agreement with respect to the value of the stock. The IRS has also made parallel claims regarding the restricted stock units against the Former Officers of the Company. The IRS has asserted that the Former Officers received ordinary income from the stock grants, and that they owe additional personal income taxes based on the fair market value of the stock. The Former Officers’ cases, unlike the Company’s case, are pending before the United States Tax Court. In the Tax Court litigation, the Former Officers are challenging the IRS’s determinations regarding the fair market value of the restricted stock grants on October 1, 2014. The Former Officers have separate counsel from the Company. The same IRS Appeals Officer and Revenue Agents assigned to the Company’s case are also involved in the cases for the Former Officers. Throughout the proceedings, the Company has argued to the IRS that it is the Former Officers who are directly and principally liable for the amount of any tax due, and not the Company.

The Former Officers cases were scheduled for trial in Tax Court on March 9, 2020. The trial of the cases was continued by the Court on February 4, 2020. The basis for the continuance was that the IRS and the Former Officers had made progress toward a settlement of the valuation issue involving the grants of the restricted stock. The outcome of these settlement negotiations will be relevant to the Company’s case. The Company is closely monitoring the settlement discussions between the IRS and the Former Officers. The Tax Court ordered the Former Officers to file status reports regarding progress of their settlement negotiations with the IRS on or before February 28, 2021. The IRS and the Former Officers filed status reports with the Tax Court on February 26, 2021. After receiving the status reports, the Tax Court issued an order directing the parties to file further status reports on or before July 9, 2021. The Tax Court has not set a trial dates in the cases of the Former Officers.

Due

On June 2, 2021, the IRS confirmed to the uncertainty associated with determining our liability for the asserted taxes and penalties, if any, and to our inability to ascertain with any reasonable degree of likelihood, as of the date of this report, the outcome of the IRS appeals process, the Company has not recorded an estimate for its potential liability, if any, associated with these taxes.

During the time period of the IRS audit and Appeals Office consideration of the Company’s case, the Company and the IRS signed a series of consents to extendthat the statutes of limitations for the assessment for bothand collection of employment tax and corporation income tax against the Company expired on December 15, 2020, without any assessments of tax or penalties. The IRS has told the Company that the employment tax and corporation income tax ofcases against the Corporation for 2014. The Company’s records show that the last consentsCompany have been closed with finality, and that the Company signed extended the statutes of limitationshas no liability for employment tax and corporation income tax for 2014 through and including December 15, 2020. The Company has no record of any consents being signed by the Company and the IRS extending the statutes of limitations beyond December 15, 2020. Based on these facts, the Company believes that the statutes of limitations for assessment of additional employment tax and corporation income tax against the Corporation for 2014 expired on December 15, 2020. The Company does not know whether the IRS agrees with the Corporation’s statements regarding the current status of the statutes of limitations described herein.2014.

On August 22, 2018, Richard Estalella filed an action against us and two other defendants in the Colorado District Court for the County of Denver, seeking damages arising out of the IRS’s assertion of tax liability and penalties relating to the 2014 restricted stock grants. We have answered Estalella’s complaint, asserted counterclaims against Estalella for his failure to ensure that all withholding taxes were paid in connection with the 2014 restricted stock grants, and filed cross-claims against two valuation firms named in the action (as well as their principals) for failing to properly value the 2014 restricted stock grants for tax purposes. Trial in the matter has been scheduled for February 7, 2022. There are no amounts accrued related to this matter.

Thematter and the Company will continue to vigorously litigate the matter.

Note 8. 10. Stock-Based Compensation

Restricted Stock

For the three and six months ended June 30, 2021, the Company granted 25,000 restricted stock awards. The fair value of this grant is approximately $29,000, which is being expensed on a straight-line basis over two years.

There were no0 restricted stock awards granted during the three months and six months ended March 31, 2021 or 2020, respectively.June 30, 2020.

As of March 31, 2021 there was no unrecognized expense for unvested restricted stock awards. For the three and six months ended March 31,June 30, 2021, and 2020, the Company recorded $0.0 and $0.1$0.0 million of stock-based compensation expense related to restricted stock.

Stock Options

For the three and six months ended March 31, 2021 andJune 30, 2020, the Company recorded no stock$0.1 and $0.2 million, respectively, of stock-based compensation expense related to options.restricted stock.

Transaction Equity Bonus

On April 5, 2021, with the appointment of the Company’s President and Chief Financial Officer, the Company granted an award where upon the occurrence of a sale of the Company, the President and Chief Financial Officer will receive 2% of the fully diluted equity of the Company. The grant will vest upon the one-year anniversary and if a sale transaction has not occurred by the two-year anniversary, then the President and Chief Financial Officer shall have the option to convert the transaction equity bonus into common shares. The fair value of this grant is approximately $1.0 million, which is being expensed on a straight-line basis over one-year.

For the three and six months ended June 30, 2021, the Company recorded $0.2 million of stock-based compensation expense related to transaction awards.

For the three and six months ended June 30, 2020, the Company recorded 0 expense related to transaction awards.

Stock Options

On May 12, 2021, the Company entered into an Agreement (the “Agreement”) with Joseph Cannata (“Cannata”), pursuant to which the Company has engaged Cannata on a non-exclusive basis to assist with the growth of the Company’s energy beverage product line.

In connection with entry into the Agreement, the Company issued to Cannata an option to purchase 1,673,994 shares of the Company’s common stock at a price per share of $1.12. The option has an exercise term of 10 years (subject to potential acceleration upon a sale of the Company) and will vest in two equal tranches upon the achievement of certain net revenue milestones related to the Company’s energy beverage products with the determination in the second quarter of 2021 that it is probable the performance criteria related to the grants will be achieved. The estimated fair value of this grant is $1.9 million and was determined by using the Black-Scholes valuation model with a term of 7.5 years; annual volatility rate of 205%; discount rate of 1.34%; and 0% for dividend rate. The fair value of performance-based restricted stock awards are recognized over the derived requisite vesting period beginning in the period in which they are deemed probable to vest.

For the three and six months ended June 30, 2021, the Company recorded approximately $60,000 of stock-based compensation expense related to stock options.

For the three and six months ended June 30, 2020, the Company recorded 0 expense related to stock options.

Note 9. 11. Net Income (Loss)Loss per Share

Basic net income (loss)loss per share is computed by dividing net income (loss)loss for the period by the weighted average number of shares of common stock outstanding during each period.

The following table sets forth the computation of the Company’s basic and diluted net income (loss)loss per share for the periods presented (in thousands, except share and per share data):

Schedule of Basic and Diluted Net Income (loss) Per Share

Diluted net income (loss)loss per share is computed by dividing net income (loss)loss for the period by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. The Company uses the treasury stock method to determine whether there is a dilutive effect of outstanding potentially dilutive securities, and the if-converted method to assess the dilutive effect of the convertible notes.

TheThere was no dilutive effect for the outstanding awards for the three and six months ended June 30, 2021 and 2020, as the Company reported net loss for all periods presented. However, if the Company had net income for the three and six months ended March 31, 2021. The weighted average shares of 12,373,071, which representedJune 30, 2021, the potentially dilutive securities related to Mr. Drexler’s convertible notes outstanding in 2020, were included in earnings per share computation would have been 12,544,774. If the computations for the dilutedCompany had net income per share for the three and six months ended March 31, 2021.June 30, 2020, the potentially dilutive securities included in earnings per share computation would have been 2,663,715.

The followingTotal outstanding potentially dilutive securities were excluded from the computationscomprised of the diluted net income (loss) per share, as the effectfollowing:

Schedule of the securities would be antidilutive:Outstanding Potentially Dilutive Securities